Equities research analysts predict that Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) will announce earnings of ($0.27) per share for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Adaptimmune Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.35) and the highest estimate coming in at ($0.18). Adaptimmune Therapeutics reported earnings per share of ($0.29) during the same quarter last year, which suggests a positive year-over-year growth rate of 6.9%. The company is scheduled to report its next quarterly earnings report on Thursday, March 21st.
According to Zacks, analysts expect that Adaptimmune Therapeutics will report full-year earnings of ($0.98) per share for the current financial year, with EPS estimates ranging from ($1.21) to ($0.84). For the next year, analysts expect that the business will post earnings of ($1.24) per share, with EPS estimates ranging from ($1.50) to ($0.94). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Adaptimmune Therapeutics.
Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.09. Adaptimmune Therapeutics had a negative net margin of 139.57% and a negative return on equity of 46.63%. The business had revenue of $40.79 million during the quarter, compared to analyst estimates of $29.41 million.
ADAP has been the subject of several research analyst reports. BidaskClub downgraded Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday. Zacks Investment Research downgraded Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday. ValuEngine lowered Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. Cowen reiterated a “buy” rating on shares of Adaptimmune Therapeutics in a research note on Tuesday. Finally, Raymond James cut their target price on Adaptimmune Therapeutics from $20.00 to $16.00 and set a “buy” rating on the stock in a research note on Monday, October 22nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $15.44.
In other Adaptimmune Therapeutics news, insider Gwendolyn Knowlt Binder-Scholl sold 25,000 shares of the company’s stock in a transaction on Wednesday, August 29th. The stock was sold at an average price of $10.25, for a total value of $256,250.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Enterprise Associates 14 New purchased 3,000,000 shares of the stock in a transaction dated Friday, September 7th. The shares were acquired at an average price of $1.67 per share, with a total value of $5,010,000.00. The disclosure for this purchase can be found here. Corporate insiders own 26.47% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of ADAP. Baillie Gifford & Co. raised its position in Adaptimmune Therapeutics by 18.2% in the 2nd quarter. Baillie Gifford & Co. now owns 3,033,261 shares of the biotechnology company’s stock valued at $36,005,000 after purchasing an additional 467,852 shares in the last quarter. BlackRock Inc. grew its stake in Adaptimmune Therapeutics by 2.5% during the 1st quarter. BlackRock Inc. now owns 806,952 shares of the biotechnology company’s stock worth $9,062,000 after buying an additional 19,765 shares during the last quarter. Frontier Capital Management Co. LLC grew its stake in Adaptimmune Therapeutics by 351.1% during the 3rd quarter. Frontier Capital Management Co. LLC now owns 698,694 shares of the biotechnology company’s stock worth $9,474,000 after buying an additional 543,809 shares during the last quarter. Stanley Laman Group Ltd. purchased a new position in Adaptimmune Therapeutics during the 3rd quarter worth approximately $7,665,000. Finally, JPMorgan Chase & Co. grew its stake in Adaptimmune Therapeutics by 786.0% during the 1st quarter. JPMorgan Chase & Co. now owns 185,660 shares of the biotechnology company’s stock worth $2,085,000 after buying an additional 164,704 shares during the last quarter. 58.99% of the stock is currently owned by hedge funds and other institutional investors.
Shares of ADAP stock traded down $0.48 on Friday, reaching $6.18. The company’s stock had a trading volume of 682,729 shares, compared to its average volume of 523,246. The firm has a market cap of $616.54 million, a PE ratio of -7.73 and a beta of 2.02. Adaptimmune Therapeutics has a 1 year low of $5.73 and a 1 year high of $14.63.
Adaptimmune Therapeutics Company Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.
Featured Story: What Is An Exchange-Traded Fund (ETF)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.